<?xml version="1.0" encoding="UTF-8"?>
<p id="para180">Another strategic opportunity to accelerate development of effective therapeutics across modalities is through development of broad and narrow spectrum therapeutics against priority pathogen families (
 <xref rid="tbl1" ref-type="table">table 1</xref>). Broad spectrum drugs (eg, immune modulating compounds) are inherently more useful, but subject to considerable technical risk as they advance in development. Narrow spectrum drugs are more achievable in the near term.
</p>
